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SUMMARY – Although the use of commercially manufactured hormone therapy (HT) to treat 
menopausal symptoms has declined during the past 12 years, the use of custom compounded  
HT seems to have increased. A 39-year-old woman with refractory anemia sustained premature  
ovarian insufficiency following allogeneic stem cell transplantation. After systemic biologic treatment 
(azacitidine) and corticosteroid therapy, besides extreme climacteric symptoms (Green Climacteric 
Scale, 59) and impaired quality of life, she also had elevated liver enzymes. Therefore, she was not a 
candidate for oral HT. Treatment was started with 17-beta estradiol patch 0.5 mg (Climara) together 
with micronized progesterone intravaginally, 2x100 mg (Utrogestan) for 3 months. She was not 
 satisfied, so the custom compound HT started with 17-beta estradiol 0.5 mg gel 2x/day and mi-
cronized progesterone in liposomal gel 100 mg/daily. She was much better but she complained of low 
libido, decreased sex drive and emotional instability, so 1% testosterone gel was added. Now she was 
completely satisfied, Green Climacteric Scale was 8 and liver enzymes were normal. In conclusion, 
custom compound HT has the possibility of tailoring and adjusting therapy to the individual need, 
which has been the everlasting goal in menopause medicine and should be a good option for special 
clinical cases.
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Introduction
After the Women’s Health Initiative (WHI) study 
was published in the literature1, the use of hormone 
therapy (HT) has decreased dramatically. In 2010, the 
prevalence of HT use was only 4.7% in women over 40 
years in the US as compared with 22.4% in 20002,3. 
Although data in the later WHI publication after 13-
year follow-up differed from the initial reports and did 
not show an increase in cardiovascular risk in any age 
group (with the exception of venous thrombosis), the 
majority of women still refused to use HT4. However, 
individualization is the key approach including con-
tinuous ongoing assessment and use of new diagnostic 
tools for efficacy and risk assessment, and therapeutic 
adjustments as necessary; all these will ensure the best 
welfare of postmenopausal women5.
Custom compounded HT could be a form of per-
sonalized medicine whereby the dose, regimen and 
dosage forms are customized and based on the patient 
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symptoms, hormone levels and personal preferences6. 
Since the Food and Drug Administration (FDA) ap-
proved HT, it has become the gold standard for thera-
peutic purposes; however, there are some special cases 
where FDA HT products do not fulfill individual pa-
tient demands. Therefore, in our case report, we pres-
ent a patient with premature ovarian insufficiency 
(POI) because of refractory anemia and allogeneic 
stem cell transplantation, which seriously impaired her 
quality of life (QoL).
Case Report
A 39-year-old woman presented with a one-year 
history of amenorrhea. She had regular menstrual cy-
cles from the age of 14 until after the allogeneic stem 
cell transplant for refractory anemia with excess blasts 
in September 2012. The post transplant period was 
complicated with chronic graft versus host disease 
(GvHD) of the skin and mucosa. She was treated with 
a combination of sirolimus and corticosteroids, which 
both were discontinued in July 2013, i.e. two months 
before examination at our institution. She continued 
taking therapy with mycophenolate until December 
2014 when GvHD remission occurred and therapy 
was stopped. She remained in disease remission for 3.5 
years after the transplant.
At presentation, she had normal body weight with 
body mass index of 21. She had normal secondary 
sexual characteristics, no signs of androgenism and no 
galactorrhea. She had very severe hot flushing and 
sweating at night, was unable to sleep and found ex-
treme difficulty in concentrating. Her libido was sig-
nificantly decreased. Her DEXA T-score L1-L4 was 
-1.6 SD, left femoral neck -0.2, total left hip -0.1 SD. 
She had no prior fragility fracture. Hormonal work-up 
confirmed elevated follicle-stimulating hormone, nor-
mal thyroid-stimulating hormone, normal prolactin, 
and normal basal and adrenocorticotropic hormone 
(ACTH) stimulated cortisol levels. Pelvic ultrasound 
examination showed small uterus with atrophic endo-
metrium and involutive ovaries. Antimüllerian hor-
mone or antral follicle count were not assessed since 
the patient declined to be referred to the Reproductive 
Unit, Department of Obstetrics and Gynecology, Uni-
versity Medical Centre Ljubljana, where these bio-
markers are routinely assessed because she was not 
interested in evaluation of her ovarian reserve. We 
concluded that previous chemotherapy with multiple 
agents, including high dose busulfan and cyclophos-
phamide for stem cell transplant conditioning had led 
to premature ovarian failure causing her severe climac-
teric problems. Unfortunately, her liver enzymes were 
elevated in the post transplant period. Derangements 
of liver enzyme tests are often seen and usually attrib-
uted to drug interactions after allogeneic stem cell 
transplant. In addition, GvHD is a complication oc-
curring in about half of these patients and in its acute 
form can affect the skin, liver and gut but is commonly 
seen as an overlapping syndrome affecting several or-
gans. Due to elevated liver enzymes, the patient could 
not take oral HT, therefore another non-oral option 
should have been administered to improve her impaired 
QoL. The climacteric score sheet based on the Greene 
Climacteric Scale was obtained to objectify her com-
plaints (Table 1). The hormones and liver enzyme 
laboratory tests before HT are reported in Table 2.
At first, the following FDA approved HT was ad-
ministered: 17-beta estradiol in patch 50 mcg (Cli-
mara) once weekly + micronized progesterone 200 
mg/day intravaginally (Utrogestan). After three 
months of treatment, the Green Climacteric Scale of 
climacteric symptoms was repeated. There was no 
change in terms of QoL improvement related to the 
severity of climacteric symptoms. The patient’s score 
was 13 for anxiety, 10 for depression, 3 for sexual, 23 
for psychological, 2 for physical, and 4 for vasomotor 
complaints. She was not satisfied with estrogen patch, 
she had allergic reactions around the patch, and com-
plained of severe headache especially the first 2 days 
after the patch had been pasted. Therefore, the route of 
HT administration was switched to custom com-
pounded HT (CC HT).
The 17-beta estradiol alcoholic gel 0.05% (50 mcg/g) 
2x daily on the forearm + 10% (100 mg/g) micronized 
progesterone liposomal gel 2x daily on the chest was ad-
ministered. After 3 months, the patient felt much better, 
with no vasomotor symptoms, but still had emotional 
instability and no libido. So the local 2% testosterone 
thick non-alcoholic gel 1x daily on the clitoris and labia 
for 2 months (to induce libido) was added, and then 
switched to systemic 1% testosterone micro in liposo-
mal gel. After 3 months of this treatment, the patient 
achieved complete satisfaction. The Green Climacteric 
Scale symptoms are shown in Table 3.
Three months after the CC HT was started, the 
hormone and liver enzyme laboratory tests were re-
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peated (Table 4). We observed normalization of alka-
line phosphatase, AST and ALT, and a significant de-
crease in gamma-glutamyl transferase, which were at-
tributable to the successful GvHD treatment and im-
munosuppressive treatment cessation.
Discussion
Premature ovarian insufficiency is very common in 
women following allogeneic stem cell transplant. Ova-
ries are more susceptible with higher doses of chemo-
therapeutic agents, longer duration of treatment, and 
use of multiple agents7. Artificial premature ovarian 
failure seemed to be abrupt cessation of reproductive 
hormonal function which led to impaired QoL. There-
fore, HT was extremely important not only to improve 
her QoL but also to resume her normal life8. Usually, 
for women with POI, a higher dose of estrogen is 
needed and maintained until the age of natural meno-
pause8,9.
Hormone therapy was the gold standard to enable 
women’s life back, so tailoring the dose according to 
Table 2. Sexual hormones and liver enzymes before hormone therapy
Sexual hormones before HT Liver enzymes before HT
S-estradiol, 0.081nmo/L (0-0.11) S-alkaline phosphatase, 3.25 μkat/L (1.74)*
S-progesterone, 0.64 nmol/L (0.2-3.2) S-AST, 1.36 μkat/L (0.52)*
S-testosterone, 0.1 nmol/L (0.3-2.0)* S-ALT, 2.82 μkat/L (0.56)*
S-DHEAS, 0.9 nmol/L (3.6-12.9)* S-γ-GT, 7.49 μkat/L (0.63)*
S-FSH, 92 nmol/L*
S-LH, 31 nmol/L*
S-cortisol (basal), 238 nmol/L (101-536) 
ACTH stimulated cortisol, 632 nmol/L
*out of the normal range; S = serum; DHEAS = dehydroepiandrosterone sulfate; FSH = follicle-stimulating hor-
mone; LH = luteinizing hormone; ACTH = adrenocorticotropic hormone; AST = aspartate aminotransferase; 
ALT = alanine aminotransferase; γ-GT = gamma-glutamyl transferase
Table 1. Green Climacteric Scale score sheet – before hormone therapy
Heart beat quickly and strongly 1 Feeling dizzy or faint 0
Feeling tense or nervous 2 Pressure or tightness in head or body 1
Difficulty in sleeping 3 Parts of body feeling numb or tingling 0
Excitable 3 Headaches 1
Attacks of panic 2 Muscle or joint pains 0
Difficulty in concentrating 3 Loss of feeling in hands or feet 0
Feeling tired or lacking in energy 2 Breathing difficulties 0
Loss of interest in most things 2 Hot flushes 3
Feeling unhappy or depressed 2 Sweating at night 3
Crying spells 2 Loss of interest in sex 3
Anxiety Depression Sexual Psychological Physical Vasomotor
Average >10 >10 7 3 2
Woman
Average
Menopausal >10 >10 12 6 4
Woman
Score 14 10 3 24 2 6
The severity of problem is scored as follows: score 0 = none; 1 = mild; 2 = moderate; 3 = severe
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the individual purpose was extremely important. The 
FDA approved HT satisfied most of the purposes for 
postmenopausal women, unfortunately, there were 
some exceptions.
The new International Menopause Society (IMS) 
recommendations for women’s midlife health and hor-
mone therapy9 do not recommend using so-called 
‘bio-identical hormones’ in the form of CC HT. Nev-
ertheless, in our case, there were some objective ob-
stacles that forced us to prescribe CC HT. Firstly, the 
woman had impaired liver function. Therefore, oral 
HT use was contraindicated concerning ‘the first pass 
through the liver’. Secondly, in Slovenia, there was a 
lack of transdermal FDA HT due to poor interest in 
HT use. Only one matrix patch system was available 
(17-beta estradiol, Climara 50 mcg). There was no gel 
or cream, either for estrogen or progesterone use. 
Moreover, transdermal testosterone therapy available 
in the dose appropriate for the woman was not FDA 
approved; the testosterone cream was available only in 
Australia10.
Many CC HT prescribers worldwide have mixed 
estrogens in the form of Bi-Est (estradiol + estrone) or 
Tri-Est (estradiol + estrone + estriol), which is unnec-
essary either in terms of hormone metabolism or post-
menopausal hormone levels. Estradiol is the main hor-
Table 4. Sex hormones and liver enzymes 3 months after custom compounded transdermal hormone 
therapy (CC HT) use
Sex hormones after 3 months of CC HT Liver enzymes after 3 months of CC HT
S-progesterone. 3.08 nmol/L (-3.2nmol/L) S-alkaline phosphatase. 1.66
S-estradiol, 0.33 nmol/L (0-0.11 nmol/L) S-AST, 0.37
S-SHBG, 31 nmol/L (26.1-110.0 nmol/L) S-ALT, 0.37
S-testosterone (free), 16.1 nmol/L (3.5-20.9 nmol/L) S-γ-GT, 2.13*
S-FSH, 42.7 nmol/L
S-LH, 23.7 nmol/L
*out of the normal range; S = serum; SHBG = sex hormone binding globulin; FSH = follicle-stimulating hormone; LH = 
luteinizing hormone; AST = aspartate aminotransferase; ALT = alanine aminotransferase; γ-GT = gamma-glutamyl trans-
ferase
Table 3. Green Climacteric Scale after the custom compounded transdermal hormone therapy use
Heart beat quickly and strongly 0 Feeling dizzy or faint 0
Feeling tense or nervous 0 Pressure or tightness in head or body 0
Difficulty in sleeping 0 Parts of body feeling numb or tingling 0
Excitable 1 Headaches 1
Attacks of panic 0 Muscle or joint pains 0
Difficulty in concentrating 0 Loss of feeling in hands or feet 0
Feeling tired or lacking in energy 0 Breathing difficulties 0
Loss of interest in most things 0 Hot flushes 1
Feeling unhappy or depressed 0 Sweating at night 1
Crying spells 1 Loss of interest in sex 1
Anxiety Depression Sexual Psychological Physical Vasomotor
Average >10 >10 7 3 2
Woman
Average
Menopausal >10 >10 12 6 4
Woman
Score 1 1 1 2 1 2
The severity of problem is scored as follows: score 0 = none; 1 = mild; 2 = moderate; 3 = severe
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mone produced by the ovary that is decreased signifi-
cantly in postmenopause; estriol is a degraded product 
of estradiol; and estrone is a hormone that remains 
almost at the same premenopausal level due to extra-
genital production from the androgen11-14. So, a mix-
ture of all estrogens should not improve QoL in post-
menopausal women better than estradiol alone.
Salivary or serum hormone testing is not necessary, 
especially in order to adjust the dose of the hormone 
regarding hormone levels in postmenopausal women. 
There are at least two reasons why hormone testing is 
not appropriate for adjusting the dose of the hor-
mones: first, estrogen, as well as progesterone or tes-
tosterone, have a pulsatile hormone release, so the con-
centration in serum or saliva changes several times a 
day; and second, hormone release is connected with 
dietary patterns and interactions with other medica-
tions, so the hormone levels in serum or saliva need 
not necessarily reflect the hormone levels in the target 
organ15,16. Hormone testing is reasonable in women 
with POI to examine the basal pretreatment hormone 
levels, and repeat testing after 3 months of therapy to 
follow-up the body response to hormone treatment 
according to the route of administration. Thus, hor-
mone testing should not be the basis for adjusting the 
HT dose, but rather an opportunity for patient follow 
up concerning the prescribed dose and route of admin-
istration.
Recent studies confirmed that the risk of venous 
thromboembolism, as well as its impact on fibrinolytic 
and coagulation parameters varied according to HT 
formulation17-21. The greatest were recorded in the us-
ers of oral estrogen-progestin HT. Transdermal route 
of administration seems to be much safer, with less 
side effects concerning thrombotic risk22.
Using transdermal micronized progesterone was an 
issue of great concern regarding endometrial safety. 
The effectiveness of these preparations in protecting 
the endometrium is controversial due to the very low 
serum levels that are achieved. A recent publication 
has finally confirmed that topical alcohol-based gels 
appear to yield luteal-phase serum progesterone levels 
which satisfactorily protect the endometrium23. We 
used liposomal gel, which ensures high bioavailability 
and deep penetration of progesterone, even better than 
alcohol-based gel24,25. The 10% progesterone liposomal 
gel twice daily enables 200 mg micronized progester-
one, which ensures safe endometrial protection.
In conclusion, our tasks as practitioners should be 
the responsibility to achieve the best QoL in our pa-
tients with special circumstances, using either FDA 
approved HT with natural hormones, or CCHT, ful-
filling the criteria of individualization and tailoring 
therapy upon personal needs. Therefore, we could 
achieve the criteria of good clinical practice in meno-
pausal medicine.
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Sažetak
INDIVIDUALIZACIJA MAGISTRALNOG HORMONSKOG LIJEČENJA  
KOD BOLESNICE S KEMOTERAPIJOM INDUCIRANOM PRIJEVREMENOM  
INSUFICIJENCIJOM JAJNIKA I SMANJENOM JETRENOM FUNKCIJOM: PRIKAZ SLUČAJA
D. Franić, M. Sever, A. Janež, M. Franić-Ivanišević i M. Jensterle-Sever
Premda je upotreba komercijalno pripravljene hormonske terapije u liječenju klimakteričnih simptoma u posljednjih 12 
godina u padu, čini se da je upotreba magistralnih hormonskih pripravaka u porastu. Žena u dobi od 39 godina s refraktor-
nom anemijom doživjela je prijevremenu insuficijenciju jajnika nakon transplantacije matičnih stanica. Nakon sistemskog 
biološkog liječenja azacitidinom i kortikosteroidima, uz izrazite klimakterične tegobe (Greenov indeks 59) i smanjenu kva-
litetu života imala je povišene jetrene enzime. Zbog toga nije bila kandidat za oralnu hormonsku terapiju. Započeto je liječe-
nje 17-beta estradiolom u obliku naljepka od 0,5 mg (Climara) zajedno s mikroniziranim progesteronom intravaginalno 
2x100 mg (Utrogestan) kroz 3 mjeseca. Nije bila zadovoljna terapijom pa su joj propisani magistralno pripravljeni hormoni. 
Započelo se s primjenom 17-beta estradiola u obliku 0,5 mg gela 2x/dan i mikroniziranog progesterona u liposomalnom gelu 
100 mg/dnevno. Bolje se je osjećala, ali još uvijek se žalila na smanjeni libido i emocionalnu nestabilnost pa je dodan 1% 
 testosteron. Sad je bila potpuno zadovoljna terapijom, Greenova klimakterijska ljestvica bila je 8, a jetreni enzimi su se nor-
malizirali. U zaključku, magistralni hormonski pripravci pružaju mogućnost titracije i prilagođavanja terapije individualnim 
potrebama, što je stalni cilj u menopauzalnoj medicini i mogao bi biti dobra mogućnost za posebne slučajeve.
Ključne riječi: Magistralno pripravljeni hormoni; Individualizacija; Prijevremena insuficijencija jajnika
